Short Paper: Gastroenterological CancersThe first 2 years of colorectal cancer screening in Ferrara, ItalyMatarese, Vincenzo G.a; Feo, Carlo Vittoriob; Lanza, Giovannid; Fusetti, Nadiaa; Carpanelli, Maria Cristinaf; Cataldo, Serenac; Cifalà, Vivianaa; Ferretti, Stefanoe; Gafà, Robertad; Marzola, Marinac; Montanari, Enricag; Palmonari, Caterinaf; Simone, Loredanaa; Trevisani, Lucioa; Stockbrugger, Reinholda; Gullini, SergioaAuthor Information aUnit of Gastroenterology bDepartments of General Surgery cOncology dProgramme of Gastroenterological Pathology, S. Anna University Hospital of Ferrara eCancer Registry, University of Ferrara fOncological Unit, Department of Public Health, Health Authority of the Province of Ferrara gLaboratory of Clinical Pathology, Delta Hospital, Lagosanto, Ferrara, Italy Correspondence to Carlo Vittorio Feo, MD, FACS, U.O. di Clinica Chirurgica, Azienda Ospedaliero, Universitaria di Ferrara, Corso Giovecca 203, Ferrara 44121, Italy Tel: +39 0 532 237620; fax: +39 0 532 249358; e-mail: email@example.com and Vincenzo Giancarlo Matarese, MD, U.O. di Gastroenterologia e Endoscopia, Azienda Ospedaliera Universitaria di Ferrara, Corso Giovecca 203, 44121 Ferrara, Italy Tel: +39 0 532 237042; fax: +39 0 532 236932; e-mail: firstname.lastname@example.org Received May 12, 2010 Accepted November 14, 2010 European Journal of Cancer Prevention: May 2011 - Volume 20 - Issue 3 - p 166-168 doi: 10.1097/CEJ.0b013e3283429ea3 Buy Metrics Abstract We report on the first screening round in the District of Ferrara, a region of Emilia-Romagna, carried out between March 2005 and March 2007 to illustrate the effort of colorectal cancer (CRC) screening from administration and information to therapy and follow-up. After invitation of 38 344 persons aged 50–69 years (28.5%), 19 480 (50.8%) accepted the immunological faecal occult blood test, with 1 149 (6%) resulting positive. One thousand and one individuals (88.2%) who tested positive for immunological faecal occult blood test accepted examination by either colonoscopy (99.5%) or barium enema (0.5%). Out of 996 screenees having a colonoscopy, 231 had low-risk adenomas (23.2%) and 239 had high-risk adenomas (24%), and were treated endoscopically (96%) or surgically (4%). Ninety-one cancers were diagnosed in 9.1% of colonoscopies (Dukes stadia: A, 58.2%; B, 19.8%; C, 18.7%; D, 3.3%). Fourteen cancers (all in polyps) were treated endoscopically, and the remaining 77 were treated by surgery. One Dukes B patient and 13 of 17 Dukes C patients received adjuvant chemotherapy. Three Dukes D patients had chemotherapy only. During the 2-year study period, 87 screenees had a follow-up colonoscopy: no neoplasia was found in 35 patients initially diagnosed with cancer; low-risk adenomas were found in 31 of 52 patients with initial high-risk adenomas. In conclusion, the first CRC screening round in Ferrara was easy to organize, had a high acceptance, and detected 91 cancers (78% of which were in Dukes stages A and B, compared with only 40% in sporadic CRC in the same background population). Chemotherapy was necessary in 17 cases. This report may motivate other health authorities to initiate CRC screening campaigns. © 2011 Lippincott Williams & Wilkins, Inc.